These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 32102539)

  • 41. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
    Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor-Positive and HER-2-Negative Breast Cancer with Neoadjuvant Chemotherapy.
    Lee EG; Lee DE; Kim HH; Han JH; Lee S; Kang HS; Lee ES; Chae H; Sim SH; Lee KS; Kwon Y; Jung SY
    Cancer Res Treat; 2023 Apr; 55(2):542-550. PubMed ID: 36097802
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
    Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
    Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.
    Asano Y; Kashiwagi S; Goto W; Kurata K; Noda S; Takashima T; Onoda N; Tanaka S; Ohsawa M; Hirakawa K
    Br J Surg; 2016 Jun; 103(7):845-54. PubMed ID: 26953091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Abdelrahman AE; Rashed HE; MostafaToam ; Omar A; Abdelhamid MI; Matar I
    Ann Diagn Pathol; 2021 Apr; 51():151676. PubMed ID: 33360026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation.
    McNamara KM; Yoda T; Miki Y; Chanplakorn N; Wongwaisayawan S; Incharoen P; Kongdan Y; Wang L; Takagi K; Mayu T; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Tamaki K; Ishida T; Ohuchi N; Sasano H
    Cancer Sci; 2013 May; 104(5):639-46. PubMed ID: 23373898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Analysis of predictive effect of Androgen receptor on the response to neoadjuvant chemotherapy in breast cancer patients].
    Zhu JJ; Jiao DC; Qiao JH; Wang LN; Ma YZ; Lu ZD; Liu ZZ
    Zhonghua Yi Xue Za Zhi; 2018 Feb; 98(8):601-605. PubMed ID: 29534389
    [No Abstract]   [Full Text] [Related]  

  • 53. Phosphorylation of androgen receptors at serine 515 is a potential prognostic marker for triple negative breast cancer.
    Roseweir AK; McCall P; Scott A; Liew B; Lim Z; Mallon EA; Edwards J
    Oncotarget; 2017 Jun; 8(23):37172-37185. PubMed ID: 28415597
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review.
    Muhammad A; Forcados GE; Katsayal BS; Bako RS; Aminu S; Sadiq IZ; Abubakar MB; Yusuf AP; Malami I; Faruk M; Ibrahim S; Pase PA; Ahmed S; Abubakar IB; Abubakar M; Yates C
    Epigenomics; 2022 Jun; 14(11):711-726. PubMed ID: 35473304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy.
    Shi Z; Liu Y; Zhang S; Cai S; Liu X; Meng J; Zhang J
    Discov Oncol; 2023 Apr; 14(1):49. PubMed ID: 37099044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
    Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
    Gerber B; Loibl S; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Nekljudova V; Untch M; von Minckwitz G;
    Ann Oncol; 2013 Dec; 24(12):2978-84. PubMed ID: 24136883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.
    Wang RX; Chen S; Jin X; Shao ZM
    Sci Rep; 2016 Jul; 6():30091. PubMed ID: 27426056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer.
    Riaz N; Idress R; Habib S; Lalani EN
    Front Oncol; 2020; 10():1083. PubMed ID: 32850312
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.